Our team
Scientific Advisory Board
Dr. Toni Pérez
Chairman, Clinical Advisory Board


José Miguel Lizcano, PhD
Chairman, Scientific Advisory Board


Dr. Pere Gascón


Dr. Jordi Rodón


Miguel F. Segura, PhD


Dra. Soledad Gallego


Antoni Martinez-Tobed, PhD
He worked for 27 years at the research center of Almirall, SA, as head of the pharmacokinetics and metabolism department, director of preclinical development and preclinical scientific director.
Antoni has a comprehensive knowledge of preclinical drug development, including bioanalysis, pharmacokinetics, metabolism, toxicology and clinical pharmacology, gained through over 35 years of experience in pharmaceutical companies and CROs.
He has a wide experience in assessment of preclinical and clinical pharmacology dossiers in development phases, and contributed to marketing approval of several new drugs in Europe, USA and Japan.


Jordi Espadaler, PhD
Research Advisor and co-Founder
Jordi obtained a BSc/MSc degree in biochemistry from the Autonomous University of Barcelona and also a PhD degree (Doctorate Extraordinary Award) from the same University. During his doctorate, Dr. Espadaler collaborated actively with Prof. Andrej Săli, a world-recognized expert in structural biology, and did several stays in his laboratory, both at the Rockefeller University (New York) and the University of California San Francisco.
In 2006 he joined AB-Biotics SA when the company had just two employees and helped it to grow from a small start-up to a publicly traded company with around 40 employees.
Jordi has published 10 articles in peer-reviewed journals and 3 patents (two of them are international patents), and is also a visiting professor since 2008 at the Master of Bioengineering of the Institut Químic de Sarrià (Ramon Llull University, Barcelona).
In 2009 Jordi cofounded Ability Pharmaceuticals, SL to become its Vice-President, Drug Discovery in September 2009.


LATEST NEWS
Press Release
Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + infoPress Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + infoPress Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + infoPress Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + infoPress Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + infoPress Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + infoPress Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + infoPress Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + infoPress Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info